Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Bayer Healthcare Pharma v. Watson Pharma, No. 12-1397 (Fed. Cir. Apr. 16, 2013)

Reversed
Invalidity (§ 102/§ 103) Summary Judgment
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 12-1397
Also Docketed
No. 12-1398, No. 12-1400, No. 12-1424 (consolidated; same document)
Decided
April 16, 2013
Judge
Lourie, J.
Document
Precedential Opinion
Length
16 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

In these consolidated patent infringement actions, g e- neric pharmaceutical manufacturers Watson Pharmace u- ticals, Inc., Watson Laboratories, Inc., Sandoz, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc. (collectively, the “Defendants”) appeal from the final judgments of the United States District Court for the District of Nevada in favor of Plaintiffs- Appellees Bayer Healthcare Pharm a- ceuticals, Inc. and Bayer Schering Pharma AG (collectiv e- ly, “Bayer”).

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error